Stryker closed the sale of its OP-1 product family for use in orthopedic bone applications to Olympus Corp., according to a company news release.
The products include OP-1 Implant, OP-1 Putty, Opgenra and Osigraft. The transaction also includes the sale of the manufacturing facility in Lebanon, N.H.
Read the Stryker release on the transaction.
Read other coverage on Stryker:
- Stryker Acquires Boston Scientific Corp.’s Neurovascular Business for $1.5B
- Stryker’s David Veino: In Support of Vertebroplasty
- Stryker Receives Two Subpoenas for Device Marketing
The products include OP-1 Implant, OP-1 Putty, Opgenra and Osigraft. The transaction also includes the sale of the manufacturing facility in Lebanon, N.H.
Read the Stryker release on the transaction.
Read other coverage on Stryker:
- Stryker Acquires Boston Scientific Corp.’s Neurovascular Business for $1.5B
- Stryker’s David Veino: In Support of Vertebroplasty
- Stryker Receives Two Subpoenas for Device Marketing